Potassium perchlorate 200mg capsules
Potassium perchlorate is an inorganic salt with the chemical formula KClO4.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Potassium perchlorate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 23 studies.
2018–2026
Showing all 23 studies, sorted by most relevant.
Andrew W. Marsh, Andy X. Zheng, Gwendolyn T. Wang, et al.
Combustion and Flame, 2023
Rongcai Zi, Zhiyue Han, Yue Yu, et al.
ACS Omega, 2023
Ammonium perchlorate (AP) has been widely used as an oxidizer in propellants and military mixed explosives in recent years. However, its high characteristic signal, environmental pollution, and poor detonation performance have prompted the industry to seek alternatives to AP. Ammonium nitrate (AN) is a suitable substitute due to its low characteristic signal, lack of pollution, and excellent detonation performance. However, its room-temperature phase transition and hygroscopicity affect its practical use. In this work, we prepared mixed crystal coprecipitation (MCC) materials of AN and potassium perchlorate (KP) using the evaporative solvent method. The characterization of AN/KP MCCs was carried out by combining TG-DSC, XRD, FT-IR, and SEM analysis, revealing that the formation of MCCs by AN and KP is due to ion exchange between the two components. AN/KP MCCs not only solve the problem of room-temperature phase transition in AN but also reduce its hygroscopicity. Furthermore, AN/KP MCCs have mechanical sensitivity, explosive performance, and specific impulse similar to pure AN, but compared to AN, AN/KP MCCs have higher density, effective oxygen content, and thermal stability. Compared with existing oxidizers AN, AP, and KP, AN/KP MCCs with high density, low sensitivity, high oxygen content, and high safety have obvious advantages and have good prospects in the application of oxidizers in solid propellants and military mixed explosives.
Abstract licence: CC BY-NC-ND
Mohammed Dourari, A. F. Tarchoun, D. Trache, et al.
Journal of Energetic Materials, 2023
Miles C. Rehwoldt, Yong Yang, Haiyang Wang, et al.
Journal of Physical Chemistry C, 2018
Yang Qin, Jie Liu, Jiangbao Zeng, et al.
Propellants, Explosives, Pyrotechnics, 2024
Vraneš MB, Čapelja E, Karaman M, et al.
2025
Imidazolium-based ionic liquids bearing a homologous series of oxychlorine anions—1-butyl-3-methylimidazolium chlorite, chlorate, and perchlorate—were synthesized and characterized to relate anion oxygenation to density, thermal expansivity, viscosity, electrical and molar conductivity, ionicity, and antimicrobial performance. Temperature-dependent measurements were carried out from 293.15 to 323.15 K: density and viscosity were recorded and modeled to obtain thermal expansion coefficients; electrical and molar conductivities were measured under identical conditions; and activation parameters were extracted by Arrhenius analysis for viscous flow and for conductivity. Ionicity was assessed from Walden plots and quantified by vertical deviation from the potassium-chloride reference (Angell approach). Complementary DFT calculations provided optimized ion-pair geometries, noncovalent contact patterns, molecular electrostatic potential maps, and frontier-orbital descriptors. In silico ADMET properties were computed to contextualize pharmacokinetic and safety flags. Antimicrobial activity was evaluated by broth microdilution against Escherichia coli, Staphylococcus aureus, Bacillus cereus, and Candida quilliermondii; [Bmim]Cl was included as a comparator to isolate the effect of anion oxygenation. The combined experimental–computational workflow delineates how chlorite, chlorate, and perchlorate shape physicochemical behavior, ionicity, and bioactivity in [Bmim] ionic liquids, providing design guidance for future applications.
Abstract licence: CC BY
Murphy DM, Abou-Ghanem M, Ahern AT, et al.
2025
Perchlorate is a toxic, regulated contaminant in drinking water. According to previous isotopic studies, much of the perchlorate deposited to the Earth’s surface is formed in the atmosphere, with 36 Cl suggesting a large contribution from the stratosphere. Here, we present measurements of perchlorate in stratospheric aerosol particles and confirm that the stratosphere is an important source of perchlorate, whereas we did not observe production in the troposphere. Mass mixing ratios of aerosol perchlorate in the stratosphere were 1 to 10 parts per trillion by mass (pptm), with the highest concentrations observed in summer and in the Southern Hemisphere. Almost all of the perchlorate is in biomass burning and nitrogen-rich particles, despite those types contributing only a few percent of the aerosol particles. Such particles are less acidic than the majority of sulfuric acid particles. If the formation of perchlorate is sensitive to acidity, then the injection of some materials for solar radiation modification might significantly increase the global production of perchlorate.
Abstract licence: CC BY-NC-ND
Wang N, Xu W, Wang W, et al.
2026
- Sewage
- Waste Disposal, Fluid
- Potassium Compounds
L.V. Shkala, T.Y. Malchevska, O.M. Plienova, et al.
Mìžnarodnij Endokrinologìčnij Žurnal, 2024
Background. Treatment of patients with comorbid pathology, including hypertension, coronary heart disease with atrial fibrillation, often requires the use of amiodarone. Unfortunately, the latter in some cases is accompanied by complications, including thyroid dysfunction. The most serious situation develops when amiodarone-induced thyrotoxicosis occurs, which leads to an additional toxic effect on the myocardium and changes in the sensitivity of the cardiovascular system to catecholamines. The manifestation of amiodarone-induced thyrotoxicosis is not always typical, which causes certain difficulties in diagnosis and treatment, especially in geriatric patients with comorbid conditions. The purpose of the study: to analyze a clinical case of amiodarone-induced thyrotoxicosis type 1 in an elderly patient suffering from hypertension and coronary heart disease with a previous myocardial infarction, heart rhythm disorders; to find out the peculiarities of clinical manifestations of thyroid dysfunction, approaches to diagnosis and treatment. Materials and methods. A clinical case of treatment of a patient with cardiovascular pathology complicated by the development of thyroid dysfunction when using amiodarone is considered: the data of medical history, objective examination, results of laboratory and instrumental research and treatment outcomes are presented and analyzed. Results. Patient P. aged 88 years old was hospitalized to the cardiology department with clinical signs of thyrotoxic cardiomyopathy, encephalopathy, myopathy, dermopathy. He has been sick for about 45 years, has a history of myocardial infarction; received antihypertensive drugs, statins, nitrates, and antithrombotic drugs on a permanent basis. Given the severity of the condition and the occurrence of atrial fibrillation, amiodarone 200 mg daily was prescribed a year ago. Examination of the patient revealed a significant weight loss, signs of heart failure stage IIA with a decrease in ejection fraction to 34–36 %, combined rhythm disturbances, in particular atrial fibrillation. According to the laboratory and instrumental examination, there was a sharp decrease in thyroid-stimulating hormone to 0.007 μIU/ml with a moderate increase in free T4 and almost normal size of the thyroid gland, moderately increased echogenicity with areas of hypervascularization and a small heterogeneous node in the right lobe. In addition, an increase in erythrocyte sedimentation rate, mild anemia, and slight hypercreatininemia were observed. Taking into account the comorbid pathology, the age of the patient, changes in the thyroid gland simultaneously with thyroid dysfunction, progression of heart failure and heart rhythm disturbances against the background of long-term amiodarone administration, a diagnosis of amiodarone-induced thyrotoxicosis type 1 was made. First of all, amiodarone was discontinued, thiamazole 20 mg daily was prescribed, as well as anti-anemic and sedative drugs. Potassium perchlorate was not used. After four months, it was possible to achieve an euthyroid state without adverse reactions from thyrostatic therapy. No recurrence of thyrotoxicosis was observed during the year. Conclusions. Considering that the use of amiodarone in comorbid elderly patients, including those with predominant cardiovascular manifestations, may be accompanied by damage to the thyroid gland, it is necessary to carefully monitor the state and function of the gland, both before prescribing the drug and during therapy to avoid possible development of amiodarone-induced conditions, especially thyrotoxicosis. Treatment of amiodarone-induced thyrotoxicosis type 1 must include thyrostatic therapy, with the dosage adjusted based on the patient’s age, comorbid conditions. The duration should be determined by the achievement of euthyroidism with further medical support.
Abstract licence: CC BY
Izzat Najmi Yaacob, Ezanee Gires, Adi Azrif Basri, et al.
Atmospheric Environment: X, 2025
The conventional propellant used in rocket boosters and tactical missiles commonly utilises ammonium perchlorate (AP). However, the release of harmful chloride fumes resulting from the combustion of AP during rocket launches contributes to a 1% increase in air pollution. Generally, the perchlorate-based propellants contribute to pollution by hydrochloric acid (HCl), which can contaminate launch sites and potentially deplete the ozone layer. Several techniques have been employed to convert standard AP-based composite solid propellant (CSP) into green propellant. This study designed a minimum chlorine content propellant containing potassium permanganate, KMnO 4 /AP as a dual oxidiser and examined its properties in CSP formulation. This novel KMnO 4 /AP was characterised in terms of morphological structure, elemental analysis, and thermal decomposition properties by using scanning electron microscope (SEM), energy dispersive X-ray analysis (EDX), and differential scanning calorimetry (DSC) and thermogravimetry analysis (TGA), respectively. Additionally, heat of combustion analysis was examined through bomb calorimetry. The chlorine content investigations were experimentally carried out, and the results were compared with conventional AP-based CSP using gas bubbling and Mohr’s titration method. From thermal decomposition analysis, sample KMnO 4 /AP (40:60) shifted high temperature decomposition (HTD) of AP to a lowest temperature of 331.32 °C with the highest heat release of 3721.2 J/g. Besides, sample KMnO 4 /AP (80:20) shows the highest reduction of chlorine concentration content with a reduction percentage of 58.25%. Besides, KMnO 4 /AP (40:60) sample resulted in the highest value of heat of combustion with a value of 1254.01 cal/g. This study contributes to the development of environmentally friendly and sustainable oxidisers for solid rocket propellant applications. • Morphological analysis using Scanning Electron Microscopy (SEM) showed that composite solid propellant (CSP) samples appeared darker and rougher as the potassium permanganate (KMnO 4 ) to ammonium perchlorate (AP) ratio increased. • The KMnO 4 /AP (40:60) CSP sample showed the best catalytic performance by reducing AP's HTD from 392.1 °C to 331.32 °C and releasing the most heat at 3721.2 J/g during decomposition. • KMnO 4 /AP (40:60) CSP sample exhibits the highest heat of combustion value of 1254.01cal/g, thus exhibits the highest combustion efficiency percentage of 100.2%. • A higher ratio of KMnO 4 /AP results in a higher percentage of decrease in chlorine concentration, as the KMnO 4 /AP CSP (80:20) sample resulted in the largest reduction of 58.25% in chlorine content. • This study will contribute to the development of environmentally friendly oxidiser in which providing a promising candidate for solid rocket motor applications.
Abstract licence: CC BY-NC-ND
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
6 to 8 hours
Mechanism
Thyroxine (T4) and tri-iodothyronine (T3) are major thyroid hormones, or iodothy…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
3 hours
[A32611]…
Half-life
6 to 8 hours
[A32611]
Protein binding
[A32613]
Volume of distribution
[A32613]…
Metabolism
[L2364]
Elimination
95%
[A32611]…
Clearance
[A32613]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1168 interactions
[L2372]
A study reports that at doses of 400 mg/d for several weeks had adverse effects such as GI irritation, skin rash, and lymphadenopathy but cited no serious complications .
[A32611]
In patients treated with 400 to 1,000 mg perchlorate daily, cases of agranulocytosis and fatal aplastic anemia have been reported. Several deaths from aplastic anemia in patients treated with perchlorate at doses of 400 to 1000 mg/d for 8 to 33 weeks were also reported .
[A32611]
The last report of fatal bone marrow toxicity related to treatment with potassium perchlorate was in the 1960s .
[A32611]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A32611]
The time to reach peak plasma levels of perchlorate is approximately 3 hours following oral administration .
[L2364]
As potassium perchlorate is an organic compound with complete ionization in water, dermal absorption through intact skin is unlikely .
[L2370]
[A32611]
[A32613]
[A32613]
[L2364]
[A32611]
It is reported that half of the total perchlorate ions administered orally are excreted during the first 5 hours post-dosing while the rest of the dose is excreted within 48 to 72 hours .
[L2364]
[A32613]
Proteins and enzymes this drug interacts with in the body
PMID:12488351 PMID:18372236 PMID:18708479 PMID:20797386 PMID:31310151 PMID:32084174 PMID:8806637 PMID:9329364
Can also mediate the transport of chlorate, thiocynate, nitrate and selenocynate PMID:12488351
Proteins that carry this drug through the body
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
ATC H03BC01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Potassium perchlorate
Additional database identifiers
Drugs Product Database (DPD)
4178
ChemSpider
22913
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11040
GeneCards
SLC5A5
UniProt Accession
SC5A5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:399
GenAtlas
ALB
GeneCards
ALB
GenBank Gene Database
V00494
GenBank Protein Database
28590
UniProt Accession
ALBU_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Molecular structure

ATC classifications (Wikidata)
Linked open data from Wikidata (Q422434), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. Molecular structure images from Wikimedia Commons.